Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
暂无分享,去创建一个
J. Slotboom | L. Kappos | C. Kamm | Y. Burren | Y. Naegelin | H. Mattle | M. El-Koussy | B. Tettenborn | O. Findling | Martin Müller | N. Goebels | F. von Bredow | G. Schwegler | D. Schött | S. Humpert | Felix Müller | Filippo Donati
[1] G. Schuler,et al. Thrombus Aspiration in ThrOmbus containing culpRiT lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI): study protocol for a randomized controlled trial , 2013, Trials.
[2] P. Sørensen,et al. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial , 2011, The Lancet Neurology.
[3] M. Sahraian,et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial , 2010, Multiple sclerosis.
[4] R. Marrie,et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis , 2010, Neurology.
[5] G. Tedeschi,et al. Atorvastatin Combined To Interferon to Verify the Efficacy (ACTIVE) in relapsing— remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy , 2010, Multiple sclerosis.
[6] C. Kamm,et al. SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology , 2009, Trials.
[7] P. Calabresi,et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a , 2009, Neurology.
[8] S. Ludwin,et al. Statin therapy inhibits remyelination in the central nervous system. , 2009, The American journal of pathology.
[9] R. Marrie,et al. Comorbidity delays diagnosis and increases disability at diagnosis in MS , 2009, Neurology.
[10] H. Althaus,et al. Negative Impact of Statins on Oligodendrocytes and Myelin Formation In Vitro and In Vivo , 2008, The Journal of Neuroscience.
[11] G. Schroth,et al. A Novel Method for Analyzing DSCE-Images With an Application to Tumor Grading , 2008, Investigative radiology.
[12] Isak Prohovnik,et al. Cross-validation of brain segmentation by SPM5 and SIENAX , 2008, Psychiatry Research: Neuroimaging.
[13] A. Reder,et al. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis , 2008, Neurology.
[14] F. Paul,et al. Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis , 2008, PloS one.
[15] I. Singh,et al. Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. , 2008, Future neurology.
[16] Hans Lassmann,et al. The Immunopathology of Multiple Sclerosis: An Overview , 2007, Brain pathology.
[17] Karl J. Friston,et al. Unified segmentation , 2005, NeuroImage.
[18] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[19] H. Hartung,et al. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. , 2004, Archives of neurology.
[20] V. Durkalski,et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis , 2004, The Lancet.
[21] S. Youssef,et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease , 2002, Nature.
[22] V. Gebski,et al. Randomisation in clinical trials , 2002, The Medical journal of Australia.
[23] F. Fazekas,et al. Statins as immunomodulators: Comparison with interferon-&bgr;1b in MS , 2002, Neurology.
[24] P. Carrieri,et al. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory , 2002, Journal of neurology, neurosurgery, and psychiatry.
[25] D. Li,et al. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. , 2001, Neurology.
[26] I. Singh,et al. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis , 2001, Journal of neuroscience research.
[27] F. Mach,et al. Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.
[28] S. Reingold,et al. The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.
[29] I. Singh,et al. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin , 1999, Neuroscience Letters.
[30] A. Gatherer,et al. Sarcoma of the Larynx , 1958, The Journal of Laryngology & Otology.
[31] L. Yeatman,et al. Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.
[32] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[33] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[34] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[35] Fifty-sixth Report. WHO Expert Committee on biological standardization. , 2007, World Health Organization technical report series.
[36] J. Abraham. The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .
[37] M. Arca. Atorvastatin , 2012, Drugs.
[38] F. Bernini,et al. Safety of HMG-CoA Reductase Inhibitors: Focus on Atorvastatin , 2004, Cardiovascular Drugs and Therapy.
[39] Paty Dw,et al. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. , 2001, Neurology.
[40] J. Carter,et al. The immunopathology of multiple sclerosis , 1991 .